Marine Lipid Fraction Pcso-524™ (lyprinol®/omega-xl®) Of The New Zealand Green-lipped Mussel Does Not Improve Pulmonary And Respiratory Muscle Function In Non-asthmatic Elite Runners

Abstract

Habitual endurance training may be associated with mild airway inflammation and subsequent deterioration in lung function. It has been shown that PCSO-524™ (Lyprinol®/Omega-XL®), a supplement extracted from the New Zealand green-lipped mussel (Perna canaliculus) comprising of up to 90 essential fatty acids, can moderate airway inflammation in humans with asthma, and in a murine-model of allergic airway disease. PURPOSE: To determine whether supplementation with PCSO-524™ (Lyprinol®/Omega-XL®) can improve pulmonary and respiratory muscle function in non-asthmatic elite runners. METHODS: 16 male, non-asthmatic elite runners participated in the study. Participants completed baseline resting pulmonary and respiratory muscle function testing, then were randomly assigned to either a treatment (PCSO-524™; 1 capsule contains 50 mg n-3 polyunsaturated fatty acids and 100 mg olive oil, n = 8) or placebo (1 capsule contains 100 mg olive oil; n = 8) group. During the supplementation period, subjects ingested 8 capsules of either treatment or placebo per day for 12 weeks. Following baseline testing, pulmonary and respiratory muscle function was assessed every two weeks throughout the 12 week supplementation period. RESULTS: Significant between-subjects main effects were not observed in forced vital capacity (FVC), forced expiratory volume in 1-second (FEV1.0), forced expiratory flow from 25-75% of lung volume (FEF25-75), peak expiratory flow (PEF), maximal voluntary ventilation (MVV), maximal inspiratory mouth pressure (PImax), maximal expiratory mouth pressure (PEmax), lung diffusion capacity (DLCO), and closing volume (CV) (all p > 0.05). A significant within-subjects main effect was observed in PEmax (p = 0.0242) and DLCO (p < 0.0001). No significant within-subject main effects were observed in FVC, FEV1.0, FEF25-75, PEF, MVV, PImax, and CV (all p > 0.05). A significant treatment by time interaction was observed in FEF25-75 (p = 0.0264) and DLCO (p = 0.0247), but no other significant interactions were observed (all p > 0.05). CONCLUSION: Supplementation with PCSO-524™ (Lyprinol®/Omega-XL®) does not improve pulmonary or respiratory muscle function in non-asthmatic elite runners.